Dr Reddy’s Cancer Drug
Dr Reddy's acquires trademark rights for Pfizer breast cancer drug
Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv
 "Dr Reddy's acquires trademark rights for Pfizer breast cancer drug")
Dr Reddy's launches cancer drug Abiraterone Acetate in US market
The drug is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson
 "Dr Reddy's launches cancer drug Abiraterone Acetate in US market")
Dr Reddy's gets USFDA nod to launch new ovarian cancer drug in US
BS ReporterHyderabad, 17 MayHyderabad-based Dr Reddy's Laboratories has received approval from US Food and Drug Administration (USFDA) to launch of Doxorubicin Hydrochloride Liposome injection in the US market. This product is therapeutic equivalent generic version of Doxil, a chemotherapy drug which is used in the treatment of certain types of cancer such as ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma. It is meant for intravenous use in slowing or stopping cancer cell growth. The USFDA approval was an outcome of extensive collaboration with the company's partner Natco Pharma Limited, on R&D and manufacturing capabilities, according to Dr Reddy's. "This approval represents the first of its kind for Dr Reddy's in the complex depot injectables arena," Alok Sonig, executive vice president and head of the North America Generics business at Dr Reddy's said."The approval further validates our capabilities to successfully develop and manufacture complex liposomal .
 "Dr Reddy's gets USFDA nod to launch new ovarian cancer drug in US")
